Treating the underlying causes of
Cardiac Disease
SignaCor, a UK based, clinical stage biotech company are pioneering a first-in-class therapeutic approach to symptomatic hypertrophic cardiomyopathy (HCM)
One that goes beyond symptom management to target the underlying disease pathology.
SignaCor is developing Cardiaza..
a patented, epigenetic modifying therapy. Cardiaza is the first and only treatment that harnesses DNA methylation to address multiple disease mechanisms of symptomatic hypertrophic cardiomyopathy (HCM), including established fibrosis, a key driver of disease progression.
Unlike standard of care treatments..
for symptomatic HCM that only treat symptoms of the disease, SignaCor’s innovative therapy modifies the underlying disease pathology, offering a potentially disease-reversing treatment for HCM patients.
SignaCor is dedicated to developing..
therapies that treat the underlying causes of cardiac disease, with a mission to improve the prognosis and outcomes for cardiac patients.
As a clinical-stage biotech company, spun out from Queen’s University Belfast, SignaCor is leading the way in the next generation of cardiac therapeutics, with the potential to redefine the standard of care for symptomatic HCM and other cardiac disorders.
Key features of the technology
SignaCor’s first product, Cardiaza, is a first-in-class, injectable, epigenetic modifying therapy for symptomatic HCM – an orphan designation.
The Phase 2 Clinical Trial of the therapy commences in 2025.
Cardiaza will be the first therapeutic to treat multiple underlying causes of symptomatic HCM, significantly reducing:
Pathological Fibrosis
Cardiomyocyte Hypertrophy
Inflammation
Cardiac Dysfunction
What is Symptomatic Hypertrophic Cardiomyopathy (HCM)?
Hypertrophic cardiomyopathy (HCM) is a genetic condition where the heart muscle thickens, making it harder for the heart to pump blood effectively. It’s the most common inherited heart disease, affecting 1 in 200 adults worldwide.
In symptomatic HCM, patients experience chest pain, shortness of breath, fatigue, dizziness, palpitations, or fainting, especially with exertion. These symptoms stem from either obstructed blood flow or a stiffened heart muscle.
If left untreated, HCM can lead to serious complications, including arrhythmias, heart failure, and even sudden cardiac death.
About Us
Company Overview:
SignaCor is a clinical-stage biotech company focused on discovering, developing, and commercialising first-in-class cardiac therapeutics to deliver reach patient impact.
Led by SignaCor’s Founder, Dr Chris Watson, over 10 years of research and development, between two universities (University College Dublin and Queen’s University Belfast) have been invested to provide supporting evidence for the repurposing of DNA methylation inhibitors treatment for cardiomyopathies.
The research teams at UCD and QUB...
have studied cardiac epigenetics and identified key global DNA methylation changes occurring in various cardiac pathologies.
Using a range of different in vivo cardiac models...
It has been found that DNA methylation inhibition significantly reduces pathological fibrosis, cardiomyocyte hypertrophy, inflammation, and improves cardiac structure and function.
Leading with the development of Cardiaza...
SignaCor’s mission is to develop first-class-cardiac therapies that improve the prognosis and outcome of cardiac patients globally.
SignaCor spun out of Queens University Belfast in 2024 with a mission to pioneer Cardiaza as a first-in-class therapeutic approach to symptomatic hypertrophic cardiomyopathy (HCM) — one that goes beyond symptom management to target the underlying disease pathology.
Meet our team
SignaCor consists of a multi-disciplinary team, with a diverse skill set ranging from in depth technical expertise through to clinical and commercial experience from the biotech sector.
